Loading
A phase 3 trial testing UGN-104 in bladder & urothelial cancer, now recruiting.
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer is a phase 3 interventional study registered as NCT06774131, led by UroGen Pharma, and recruiting on the registry. Official title: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC). Planned enrolment is 70 participants (estimated). The study started in 2025-08-06 and primary completion is expected in 2027-03. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares UroGen Pharma, Bladder & urothelial cancer.
Shares UroGen Pharma, Bladder & urothelial cancer.
Shares UroGen Pharma, Bladder & urothelial cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/